Losses
The 2024 and 2025 financial years closed with a loss. 2024 was the heaviest.
The 2024 and 2025 financial years closed with a loss. 2024 was the heaviest.
Of this, €4.1m falls due within a year.
Green is investment, beige is depreciation.
Ten of the last ten came late. The 2019 accounts came latest: 91 days after the end of the period.
Subsidiary with negative equity. PHARMIMPULSE · loss of €81,057 in 2025.
Lower net result than 85% of companies in retail trade. Sector median €39,880 · 5,067 companies.
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 25% of them on solvency, 18% on liquidity, 24% on profitability and 25% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Liquidity is insufficient, with a current ratio of 0.28 (0.32 in 2024), below 1. Short-term debt is 61.7% and cash 1.7% of total assets. 92.6% of the assets are financed with debt and provisions.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The company filed its last 7 accounts on average 61 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Shares in 4 companies, including CAPITOLIUM and Europhar
Board & ownership| Company | ||||
|---|---|---|---|---|
| PALATINE Etterbeek | €6.6m | €0.7m | 7.4% | 7.4 |
| PHARMACIE LIBERT Charleroi | €4.1m | €0.7m | 62.3% | 6.2 |
| HAINAPHARMA Aiseau-Presles | €4.0m | €0.9m | 50.1% | 9.3 |
| APOTHEEK BOURGUIGNON-DERAEVE Ninove | €5.3m | €1.2m | 93.5% | 6.9 |
| NERUM Heusden-Zolder | €6.5m | €1.3m | 88.3% | 5.4 |
| Apotheek Devroe Tielt | €4.3m | €1.4m | 38.3% | 6.8 |
| Apotheek Lox Leuven | €5.3m | €0.5m | 69.5% | 4.4 |
These companies have the same main activity as PALATINE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €4m and €6.5m, founded between 1983 and 1999.
PALATINE has existed since 1987. The present size dates from 2016. The gross margin rose that year from €93,611 to €624,398. On 1 January 2016 a site was added.
BLUESTONE holds 51.44% of the shares. In October 2022, the Official Gazette published the appointment of BLUESTONE as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.